Drugs / MW150
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05194163 | May 2022 → Aug 2024 | Alzheimer disease | Neurokine Therapeutics | Unknown | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MW150 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05194163 ↗ |
| Action | Inhibit | “a p38alphaMAPK kinase inhibitor” NCT05194163 ↗ |
| Modality | Small molecule | — CHEMBL4129018 ↗ |
| Route | Oral | “oral-delivered capsule of study drug” NCT05194163 ↗ |